125 related articles for article (PubMed ID: 33141923)
1. Organic Anion Transporting Polypeptide Inhibition Dramatically Increases Plasma Exposure but not Pharmacodynamic Effect nor Inferred Hepatic Intracellular Exposure of Firsocostat.
Kirby BJ; Lutz JD; Yue MS; Garrison KL; Qin AR; Ampaw L; Beysen C; Myers RP; Kearney BP; Mathias A
Clin Pharmacol Ther; 2021 May; 109(5):1334-1341. PubMed ID: 33141923
[TBL] [Abstract][Full Text] [Related]
2. Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis.
Lawitz EJ; Coste A; Poordad F; Alkhouri N; Loo N; McColgan BJ; Tarrant JM; Nguyen T; Han L; Chung C; Ray AS; McHutchison JG; Subramanian GM; Myers RP; Middleton MS; Sirlin C; Loomba R; Nyangau E; Fitch M; Li K; Hellerstein M
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1983-1991.e3. PubMed ID: 29705265
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and Safety of Firsocostat, an Acetyl-Coenzyme A Carboxylase Inhibitor, in Participants with Mild, Moderate, and Severe Hepatic Impairment.
Younis IR; Nelson C; Weber EJ; Qin AR; Watkins TR; Othman AA
J Clin Pharmacol; 2024 Jul; 64(7):878-886. PubMed ID: 38520128
[TBL] [Abstract][Full Text] [Related]
4. GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH).
Alkhouri N; Lawitz E; Noureddin M; DeFronzo R; Shulman GI
Expert Opin Investig Drugs; 2020 Feb; 29(2):135-141. PubMed ID: 31519114
[No Abstract] [Full Text] [Related]
5. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism.
Lau YY; Okochi H; Huang Y; Benet LZ
Drug Metab Dispos; 2006 Jul; 34(7):1175-81. PubMed ID: 16624870
[TBL] [Abstract][Full Text] [Related]
6. Dehydroepiandrosterone sulfate, a useful endogenous probe for evaluation of drug-drug interaction on hepatic organic anion transporting polypeptide (OATP) in cynomolgus monkeys.
Watanabe M; Watanabe T; Yabuki M; Tamai I
Drug Metab Pharmacokinet; 2015 Apr; 30(2):198-204. PubMed ID: 25989893
[TBL] [Abstract][Full Text] [Related]
7. Application of a PBPK model to elucidate the changes of systemic and liver exposures for rosuvastatin, carotegrast, and bromfenac followed by OATP inhibition in monkeys.
Cheng Y; Liang X; Hao J; Niu C; Lai Y
Clin Transl Sci; 2021 Sep; 14(5):1924-1934. PubMed ID: 34058067
[TBL] [Abstract][Full Text] [Related]
8. Effect of Rifampin-Mediated OATP1B1 and OATP1B3 Transporter Inhibition on the Pharmacokinetics of the P2Y12 Receptor Antagonist Selatogrel.
Schilling U; Dingemanse J; Voors-Pette C; Romeijn C; Dogterom P; Ufer M
Clin Transl Sci; 2020 Sep; 13(5):886-890. PubMed ID: 32166864
[TBL] [Abstract][Full Text] [Related]
9. Organic Anion-Transporting Polypeptide Genes Are Not Induced by the Pregnane X Receptor Activator Rifampin: Studies in Hepatocytes In Vitro and in Monkeys In Vivo.
Niu C; Wang Y; Zhao X; Tep S; Murakami E; Subramanian R; Smith B; Lai Y
Drug Metab Dispos; 2019 Dec; 47(12):1433-1442. PubMed ID: 31582395
[TBL] [Abstract][Full Text] [Related]
10. Comparative Evaluation of Plasma Bile Acids, Dehydroepiandrosterone Sulfate, Hexadecanedioate, and Tetradecanedioate with Coproporphyrins I and III as Markers of OATP Inhibition in Healthy Subjects.
Shen H; Chen W; Drexler DM; Mandlekar S; Holenarsipur VK; Shields EE; Langish R; Sidik K; Gan J; Humphreys WG; Marathe P; Lai Y
Drug Metab Dispos; 2017 Aug; 45(8):908-919. PubMed ID: 28576766
[TBL] [Abstract][Full Text] [Related]
11. Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition.
Lai Y; Mandlekar S; Shen H; Holenarsipur VK; Langish R; Rajanna P; Murugesan S; Gaud N; Selvam S; Date O; Cheng Y; Shipkova P; Dai J; Humphreys WG; Marathe P
J Pharmacol Exp Ther; 2016 Sep; 358(3):397-404. PubMed ID: 27317801
[TBL] [Abstract][Full Text] [Related]
12. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver.
Vavricka SR; Van Montfoort J; Ha HR; Meier PJ; Fattinger K
Hepatology; 2002 Jul; 36(1):164-72. PubMed ID: 12085361
[TBL] [Abstract][Full Text] [Related]
13. Induction of Human Intestinal and Hepatic Organic Anion Transporting Polypeptides: Where Is the Evidence for Its Relevance in Drug-Drug Interactions?
Rodrigues AD; Lai Y; Shen H; Varma MVS; Rowland A; Oswald S
Drug Metab Dispos; 2020 Mar; 48(3):205-216. PubMed ID: 31879282
[TBL] [Abstract][Full Text] [Related]
14. Acetyl-coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: A randomized, double-blind, crossover study.
Stiede K; Miao W; Blanchette HS; Beysen C; Harriman G; Harwood HJ; Kelley H; Kapeller R; Schmalbach T; Westlin WF
Hepatology; 2017 Aug; 66(2):324-334. PubMed ID: 28470676
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin.
Custodio JM; Wang H; Hao J; Lepist EI; Ray AS; Andrews J; Ling KH; Cheng A; Kearney BP; Ramanathan S
J Clin Pharmacol; 2014 Jun; 54(6):649-56. PubMed ID: 24375014
[TBL] [Abstract][Full Text] [Related]
16. Pitavastatin as an in vivo probe for studying hepatic organic anion transporting polypeptide-mediated drug-drug interactions in cynomolgus monkeys.
Takahashi T; Ohtsuka T; Yoshikawa T; Tatekawa I; Uno Y; Utoh M; Yamazaki H; Kume T
Drug Metab Dispos; 2013 Oct; 41(10):1875-82. PubMed ID: 23929936
[TBL] [Abstract][Full Text] [Related]
17. Effect of single-dose rifampin on the pharmacokinetics of warfarin in healthy volunteers.
Frymoyer A; Shugarts S; Browne M; Wu AH; Frassetto L; Benet LZ
Clin Pharmacol Ther; 2010 Oct; 88(4):540-7. PubMed ID: 20703222
[TBL] [Abstract][Full Text] [Related]
18. Absence of OATP1B (Organic Anion-Transporting Polypeptide) Induction by Rifampin in Cynomolgus Monkeys: Determination Using the Endogenous OATP1B Marker Coproporphyrin and Tissue Gene Expression.
Zhang Y; Chen C; Chen SJ; Chen XQ; Shuster DJ; Puszczalo PD; Fancher RM; Yang Z; Sinz M; Shen H
J Pharmacol Exp Ther; 2020 Oct; 375(1):139-151. PubMed ID: 32719071
[TBL] [Abstract][Full Text] [Related]
19. Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems.
Lau YY; Okochi H; Huang Y; Benet LZ
J Pharmacol Exp Ther; 2006 Feb; 316(2):762-71. PubMed ID: 16258024
[TBL] [Abstract][Full Text] [Related]
20. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine.
Simonson SG; Raza A; Martin PD; Mitchell PD; Jarcho JA; Brown CD; Windass AS; Schneck DW
Clin Pharmacol Ther; 2004 Aug; 76(2):167-77. PubMed ID: 15289793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]